Crossmark

Understanding Autologous Stem Cell as Future Minimal Invasive Modalities for Treatment

Published Online: 2022-04-05

Published Print: 2022

Authors

Tanaka, Rica
License Information

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2022-01-01
More Information

Chapter History

First Online: 5 April 2022

Disclosure Statement

: The author is a Chief Scientific Officer of ReEir Co. ReEir is a company conducting Phase II Clinical trial of ex vivo cultured peripheral blood MNCs.

Document is current